RxDoctor Payments Data

George Reiss, MD

Ophthalmology · Glendale, AZNPI 1619927969

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (45.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Glaukos Corporation at 32.2% of the total. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$73,493in general payments, 2019–2025

Across 258 payments — averaging $284.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$24K
  • Aerie Pharmaceuticals, Inc.$20K
  • W. L. Gore & Associates, Inc.$14K
  • AbbVie$5K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
  • Nova Eye, Inc.$2K
  • plus $4K from 14 others
$1,192,322in research payments, 2019–2025

Across 323 payments — averaging $3691.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$1M
  • AbbVie$149K
  • Alcon Research LLC$20K

What the payments were for

  • Consulting fees$33,65046%
  • Speaking & faculty fees$24,00233%
  • Travel & lodging$5,9768%
  • Food & beverage$8,69512%
  • Education$490%
  • Gifts$450%
  • Other$1,0771%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,493 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$371,710
Medicare patients
578
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost245$97,012
RocklatanNetarsudil Mesylat/Latanoprost153$70,150
VyzultaLatanoprostene Bunod113$49,761
CombiganBrimonidine Tartrate/Timolol54$18,054
Alphagan PBrimonidine Tartrate42$13,185
Prednisolone Acetate369$13,103
SimbrinzaBrinzolamide/Brimonidine Tart55$11,948
RhopressaNetarsudil Mesylate25$9,191
IyuzehLatanoprost/Pf17$7,675
Travoprost42$6,840
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat387$6,404
TafluprostTafluprost/Pf25$5,591
Dorzolamide-TimololDorzolamide/Timolol/Pf30$5,165
Latanoprost467$4,371
Loteprednol Etabonate23$3,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$5,307$128,252341 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$20,152$79,340178 claims
Bausch & Lomb Americas Inc.Vyzulta$339$49,761113 claims
AlconSimbrinza$798$11,94855 claims
Thea Pharma Inc.Iyuzeh$34$7,67517 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$5,123$3,81823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →